Lipoxygenase Inhibitors

IL-6, Interleukin-6, murine (mouse): Murine Interleukin-6 Interleukin 6 is a multi-functional protein that plays important roles in host defense, acute phase reactions, immune responses, and hematopoiesis. IL-6 is expressed by a variety of normal

IL-6, Interleukin-6, murine (mouse): Murine Interleukin-6 Interleukin 6 is a multi-functional protein that plays important roles in host defense, acute phase reactions, immune responses, and hematopoiesis. IL-6 is expressed by a variety of normal

Application IOX1 has been used: To eliminate viral latency in latent viruses in order to sensitize the viral infections to antiviral therapy. In histone lysine demethylase 4A (KDM4A) inhibition, to serve as a unique strategy to decrease

Application IOX2 has been used as PHD inhibitor to induce pseudo-hypoxia. Biochem/physiol Actions IOX2 is selective and potent inhibitor of prolyl hydroxylases (PHD).

Application IOX2 has been used as PHD inhibitor to induce pseudo-hypoxia. Biochem/physiol Actions IOX2 is selective and potent inhibitor of prolyl hydroxylases (PHD).

Isocitrate dehydrogenase 1 (IDH1) gene is located on human chromosome 2q33. IDH1 is present in the cytoplasm and peroxisomes.

Biochem/physiol Actions Isocitrate dehydrogenase (IDH) plays a major role in the Krebs cycle by catalyzing the oxidative decarboxylation of isocitrate. The oxidative decarboxylation of isocitrate generates &#945-ketoglutarate and NADPH.

Biochem/physiol Actions Isocitrate dehydrogenase (IDH) plays a major role in the Krebs cycle by catalyzing the oxidative decarboxylation of isocitrate. The oxidative decarboxylation of isocitrate generates &#945-ketoglutarate and NADPH.

JI-101 is an orally available multi-kinase inhibitor of VEGFR2 , PDGFRβ and EphB4 with potent anti-cancer activity.In VitroJI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95

JI-101 is an orally available multi-kinase inhibitor of VEGFR2 , PDGFRβ and EphB4 with potent anti-cancer activity.In VitroJI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95

JI-101 is an orally available multi-kinase inhibitor of VEGFR2 , PDGFRβ and EphB4 with potent anti-cancer activity.In VitroJI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95

JI-101 is an orally available multi-kinase inhibitor of VEGFR2 , PDGFRβ and EphB4 with potent anti-cancer activity.In VitroJI-101 is found to be stable in all preclinical and human liver microsomes. The % metabolized is ranged between 3.03-3.95